Extended Data Table 7 Post-hoc analyses of selected PBA-s severity subscores at Month 17 in EM Cohort B1

From: Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial